| 1237 Patients' non-medical characteristics in Multidisciplinary team meetings: Emergence and associations with medical decisions in oncology L Restivo, T Apostolidis, AD Bouhnik, S Garciaz, T Aurran, ... European Journal of Cancer 3 (51), S185-S186, 2015 | | 2015 |
| 822O Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial) S Garciaz, S Champiat, P Peterlin, K Lemmens, A de Gassart, P Brune, ... Annals of Oncology 34, S543, 2023 | | 2023 |
| 823O Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute … M Jongen-Lavrencic, A Bajel, S Garciaz, A Maiti, S Fleming, S De Button, ... Annals of Oncology 34, S543-S544, 2023 | | 2023 |
| A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations E Jabbour, E Searle, M Abdul-Hay, S Abedin, I Aldoss, AA Piérola, ... Blood 142, 57, 2023 | 18 | 2023 |
| A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. AS Stein, M Jongen-Lavrencic, S Garciaz, GA Huls, A Maiti, N Boissel, ... Journal of Clinical Oncology 41 (16_suppl), 7005-7005, 2023 | 7 | 2023 |
| A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia. NG Daver, P Montesinos, JK Altman, AS Advani, ES Wang, S Garciaz, ... Journal of Clinical Oncology 42 (16_suppl), TPS6585-TPS6585, 2024 | | 2024 |
| A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population D Blaise, S Almaghrabi, S Harbi, S Fürst, F Legrand, B Bouchacourt, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Acute immune hematological complication of oxaliplatin. A series of 3 cases S Garciaz, S Oziel-Taieb, S Dermeche, P Ries, J Vessaud, JL Raoul Tumori Journal 100 (1), e17-e19, 2014 | 6 | 2014 |
| Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a … S Garciaz, S Bertoli, DA Sallman, J Decroocq, PY Dumas, A Belhabri, ... Blood 142, 161, 2023 | 5 | 2023 |
| Allogeneic hematopoietic stem cell transplantation in a cohort of 314 advanced lymphoma patients. S Garciaz, L Castagna, J El Cheikh, S Bramanti, S Furst, R Crocchiolo, ... Journal of Clinical Oncology 32 (15_suppl), 8568-8568, 2014 | | 2014 |
| Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous … A de Masson, M Beylot-Barry, JD Bouaziz, RP de Latour, F Aubin, ... haematologica 99 (3), 527, 2014 | 83 | 2014 |
| Allogreffe de cellules souches hématopoïétiques dans 37 cas de mycosis fongoïde transformé et autres lymphomes T cutanés primitifs de stade avancé A De Masson, M Beylot-Barry, JD Bouaziz, F Aubin, S Garciaz, M d’Incan, ... Annales de Dermatologie et de Vénéréologie 140 (12), S361-S362, 2013 | | 2013 |
| Allogreffe haploidentique, une stratégie pometteuse en l'absence de donneur génoidentique: étude rétrospective de 79 patients avec un lymphome non hodgkinien en situation avancée S Garciaz | | 2015 |
| AML-110 Outcome of Acute Myeloid Leukemia Relapse After Allogenic Stem Cell Transplantation: A Single-Institution Retrospective Study Y Hicheri, C Castoldi, R Devillier, MA Hospital, E D'Incan, S Garciaz, ... Clinical Lymphoma Myeloma and Leukemia 23, S270, 2023 | | 2023 |
| An open-label, first-in-human, dose-escalation study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid … AS Stein, A Bajel, S Fleming, M Jongen-Lavrencic, S Garciaz, A Maiti, ... Blood 140 (Supplement 1), 7476-7477, 2022 | 6 | 2022 |
| Analysis of a large single institution cohort of related donors fails to detect a relation between SDF1/CXCR4 or VCAM/VLA4 genetic polymorphisms and the level of hematopoietic … S Garciaz, P Sfumato, A Granata, AM Imbert, C Fournel, B Calmels, ... PloS one 15 (3), e0228878, 2020 | 5 | 2020 |
| Autologous Stem Cell Transplantation with Bendaeam (Bendamustine, Etoposide, Cytarabine, Melphalan) As Conditioning Regimen for Non-Hodgkin’s Lymphoma and Hodgkin’s Lymphoma S Garciaz, D Coso, F Broussais, JM Schiano, B Calmels, C Saillard, ... Blood 124 (21), 2515, 2014 | | 2014 |
| Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients S Garciaz, MA Hospital, AS Alary, C Saillard, Y Hicheri, B Mohty, J Rey, ... Cancers 14 (8), 2025, 2022 | 34 | 2022 |
| Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients C Petit, C Saillard, B Mohty, Y Hicheri, F Villetard, V Maisano, ... European Journal of Haematology 112 (4), 530-537, 2024 | 3 | 2024 |
| B-cell lymphoma M Alcantara, AS Cottereau, S Garciaz, A Morel Hématologie 21 (2), 16-22, 2015 | | 2015 |
